SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?


To: Anthony Wong who wrote (5629)9/19/1998 2:06:00 PM
From: Anthony Wong  Read Replies (1) | Respond to of 9523
 
Irish Times - œ20m a year to offer Viagra on GMS
September 18, 1998

By Michael O'Regan

About 18,000 Irish men may seek the anti-impotence drug,
Viagra, when it becomes available here within a fortnight,
according to a senior official in the Department of Health.

The Department's secretary general, Mr Jerry O'Dwyer, said
that if 10 per cent of the male population - 180,000 men -
suffered from erectile dysfunction the expectation would be
that, at a minimum, only 10 per cent of them would go for
treatment.

He told the Dail Committee on Public Accounts yesterday that
if the drug was made available free under the various drugs
schemes it would cost "not less than œ7 million and perhaps up
to œ20 million" a year. The estimate was made on the basis of a
usage of four to 10 tablets a month.

He said it was hoped the expert committee set up by the
Minister for Health, Mr Cowen, to examine whether the drug
should be included in the General Medical Services (GMS)
scheme would report about three months after the drug
became available.

The committee chairman, Mr Jim Mitchell (FG), wondered
what would happen if there was a different policy relating to
GMS availability North and South.

"Remember we had the contraceptive expresses to Belfast. We
might have Viagra expresses to Belfast if there was not some
kind of co-ordination," he added.

Mr Mitchell said Viagra had the potential to be a recreational
drug and he wondered if there had been any discussions at EU
level on the implications of that. Mr O'Dwyer replied that he
was not aware of any such discussions, but there had been
contacts between various states.

What was happening overall in Europe was that there was a
waitand-see policy or a restricted regime in the distribution of
the drug. "The only real experience which anybody has at this
stage regarding pattern of usage is in America. After an initial
high level of usage there has been some drop-off because
people realise that the drug is only of value if you have certain
problems." Mr O'Dwyer said the aim was to ensure that the
drug was made available to those with a genuine medical need
for it.

Earlier, Mr Mitchell asked about the reported difference in the
cost of the tablet, adding that it was supposed to be on sale in
Britain at œ4.48 but would cost œ9 in Ireland. The chief officer
of the GMS payments board, Mr Tom Flood, said while he
could not comment on the figures, they would not be typical of
the relationship between Irish and UK prices. "For the most
part, our drug prices would almost be on par. In some cases
we would, in fact, be cheaper than products on the UK
market."

Mr O'Dwyer said any information the Department had would
suggest that the overall cost of drugs and medicines in Ireland
was one of the lowest in the OECD. He said the tablet was
produced at three strengths - 25, 50 and 100 - and the price
was different in each case. The current recommended dose
would be 50, and it would cost about œ9 for a private patient
and between œ6 and œ7 if available under the GMS.

irish-times.com